Nasdaq Inc vs Sanofi SA — how do they compare? Nasdaq Inc trades at $90.25 (market cap $51.96B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 2× Nasdaq Inc's market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| NDAQ | SNY | |
|---|---|---|
Market Cap | $51.96B | $104.83B |
Sector | Financials | Health |
52-Week High | $100.98 | $52.34 |
52-Week Low | $76.85 | $41.33 |
Enterprise Value | $59.02B | $121.32B |
Dividend Yield | 1.22% | 5.5% |
Trailing returns across standard periods
Latest headlines on both assets
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →